Archives
RCT: Subcutaneous Tirzepatide added to titrated Insulin Glargine improves glycemic control in patients with Type 2 Diabetes.
10 Feb, 2022 | 10:00h | UTCEffect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Tirzepatide for Patients With Type 2 Diabetes – JAMA
Commentary: SURPASS-5 Data: Tirzepatide Plus Insulin Glargine Improve Glycemic Control in T2D – AJMC
Related:
2021 Brazilian Thoracic Association recommendations for the management of severe asthma.
10 Feb, 2022 | 08:52h | UTC
Position statement on the care of the athlete and athletic person with diabetes.
10 Feb, 2022 | 08:49h | UTC
M-A: In patients with acute coronary syndrome undergoing percutaneous coronary intervention, short duration of dual antiplatelet therapy (DAPT) was comparable to de-escalation regarding all-cause death. De-escalation reduced the risk for adverse cardiovascular events, while short DAPT decreased major bleeding.
10 Feb, 2022 | 08:46h | UTCShort Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes – JACC: Cardiovascular Interventions (link to abstract – $ for full-text)
Commentary: Short Duration of DAPT vs. De-Escalation After PCI for ACS – American College of Cardiology
GOLD Report 2022: Global strategy for prevention, diagnosis and management of COPD.
10 Feb, 2022 | 08:53h | UTCGOLD Report 2022: Global strategy for prevention, diagnosis and management of COPD
Systematic Review: Overuse of diagnostic testing in healthcare.
10 Feb, 2022 | 08:47h | UTCOveruse of diagnostic testing in healthcare: a systematic review – BMJ Quality & Safety
Culprit medications and risk factors associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A population-based nested case–control study.
10 Feb, 2022 | 08:42h | UTC
M-A: Time to benefit for stroke reduction after blood pressure treatment in older adults.
10 Feb, 2022 | 08:44h | UTCNews Release: New research finds more intensive blood pressure treatment may prevent strokes in older adults – Wiley
Primer for artificial intelligence in primary care.
10 Feb, 2022 | 08:36h | UTCPrimer for artificial intelligence in primary care – Canadian Family Physician
Editorial: Artificial intelligence and the family physician
Medication management for heart failure with reduced ejection fraction: Clinical pearls for optimizing evidenced-informed therapy.
10 Feb, 2022 | 08:41h | UTCMedication management for heart failure with reduced ejection fraction – Canadian Family Physician
Guide to writing and publishing a scientific manuscript: Part 1—The structure.
10 Feb, 2022 | 08:35h | UTC
Short Review: Biologics for episodic and chronic migraines.
10 Feb, 2022 | 08:40h | UTCBiologics for episodic and chronic migraines – Canadian Family Physician
Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery.
10 Feb, 2022 | 08:34h | UTC
Review: Cognitive-behavioural therapy for children with irritable bowel syndrome.
10 Feb, 2022 | 08:38h | UTCCognitive-behavioural therapy for children with irritable bowel syndrome – Canadian Family Physician
Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update.
10 Feb, 2022 | 08:33h | UTC
Interstitial pneumonia with autoimmune features: challenges and controversies.
10 Feb, 2022 | 08:33h | UTC
M-A: Patients generally may return to driving 4 weeks after hip arthroscopy and 6 weeks after knee arthroscopy.
10 Feb, 2022 | 08:31h | UTC
Commentary on Twitter
Patients are generally safe to drive *4 weeks* after hip arthroscopy and *6 weeks* after knee arthroscopy. Meta-Analysis from Palma et al in ASMAR this month gives us the evidence!
Is it time to revise your instructions for your patients? 🤔https://t.co/Bcg12tX0MM pic.twitter.com/wAhJx2vS8a
— Arthroscopy Journal (@ArthroscopyJ) October 20, 2021
RCT: Apatinib improves outcomes compared to placebo in patients with locally advanced or metastatic, radioactive iodine–refractory differentiated thyroid cancer.
10 Feb, 2022 | 09:56h | UTC
Commentary on Twitter
Apatinib offered significant clinical benefits in terms of both prolonged progression-free survival and overall survival in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. https://t.co/I14AyxKZNS
— JAMA Oncology (@JAMAOnc) December 16, 2021
RCT: Home phototherapy of term neonates improves parental bonding and stress.
10 Feb, 2022 | 08:25h | UTC
Commentary on Twitter
Does treating Jaundice in babies at home, as compared to at hospital, improves parental bonding and reduces parental stress?
A new RCT published @ActaPaediatrica by Swedish researchers #EBNEOAlerts #neoEBM #FOAMNeohttps://t.co/InjkdrC5JY pic.twitter.com/BaGs86Hf8t
— Evidence-Based Neo (@EBNEO) January 3, 2022
M-A: Pain management in acute pancreatitis.
10 Feb, 2022 | 08:29h | UTC
Opinion: Development of clinical practice guidelines ‘is a mess’.
9 Feb, 2022 | 10:16h | UTCDevelopment of clinical practice guidelines ‘is a mess’ – STAT
Recommendations for management of childhood psoriasis.
10 Feb, 2022 | 08:26h | UTCRecommendations for management of childhood psoriasis – Indian Dermatology Online Journal
IDSA Updated Covid-19 Guideline now supports the use of convalescent plasma in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease.
9 Feb, 2022 | 10:15h | UTC
Commentary on Twitter
Update Alert: Revised recommendation on the use of #convalescentplasma in ambulatory patients w/ COVID-19 at high risk of progression to severe disease w/ no other treatment options.
📄: https://t.co/YRCxtdilXT#COVID19Guidelines @JGPharmD @adarsh_bhimraj @RMKGandhi @ShohamTxID pic.twitter.com/KpXnywH362
— IDSA (@IDSAInfo) February 8, 2022
European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.
9 Feb, 2022 | 10:18h | UTCRelated: IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
WHO: Two years into COVID pandemic, most countries still face significant health service disruptions.
9 Feb, 2022 | 10:13h | UTCOriginal Report: Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic – World Health Organization